RENOVORX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.243 USD | +2.73% |
|
+6.24% | -45.72% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 29.77M 2.38B |
|---|---|---|---|---|---|
| Net income 2024 * | -8M -640M | Net income 2025 * | -12M -961M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.88
x | P/E ratio 2025 * |
-3.03
x | Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.22% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.73% | ||
| 1 week | +6.24% | ||
| Current month | -7.24% | ||
| 1 month | -9.93% | ||
| 3 months | +18.38% | ||
| 6 months | +20.68% | ||
| Current year | -45.72% |
1 week
1.16
1.38
1 month
1.101.56
Current year
1.002.12
1 year
0.533.29
3 years
0.5316.74
5 years
0.5316.74
10 years
0.5316.74
| Managers | Title | Age | Since |
|---|---|---|---|
Shaun Bagai
CEO | Chief Executive Officer | 47 | 31/05/14 |
Ramtin Agah
FOU | Founder | 58 | 30/11/09 |
Ronald Kocak
DFI | Director of Finance/CFO | 67 | 30/09/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 31/12/11 |
Laurence Marton
BRD | Director/Board Member | 80 | 30/11/12 |
| Director/Board Member | 60 | 31/08/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.243 | +2.73% | 27,483 |
| 25/04/24 | 1.21 | -0.25% | 3,465 |
| 24/04/24 | 1.213 | +1.08% | 3,615 |
| 23/04/24 | 1.2 | -2.44% | 2,941 |
| 22/04/24 | 1.23 | +5.13% | 4,385 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapyâs toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.243
USD
Average target price
3.75
USD
Spread / Average Target
+201.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.72% | 29.77M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RNXT Stock
